In Forschner’s study, a cutoff value of 23.1 Mut/Mb was utilized to separate the TMB of metastatic melanoma patients into TMB low or intermediate and TMB high, which was found effective in predicting the response and overall survival under combined CTLA-4 and PD-1 antibody therapy. This evidence concerns the gene PDCD1 and metastatic melanoma.